Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free NAMSW Stock Alerts

NewAmsterdam Pharma (NAMSW) Competitors

NewAmsterdam Pharma logo
$11.00 -1.00 (-8.33%)
As of 10/6/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NAMSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Alvotech?

NewAmsterdam Pharma (NASDAQ:NAMSW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

In the previous week, Alvotech had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for Alvotech and 0 mentions for NewAmsterdam Pharma. Alvotech's average media sentiment score of 0.70 beat NewAmsterdam Pharma's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
NewAmsterdam Pharma Neutral
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats NewAmsterdam Pharma on 3 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Apollomics?

Apollomics (NASDAQ:APLMW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

In the previous week, Apollomics' average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company Overall Sentiment
Apollomics Neutral
NewAmsterdam Pharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Summary

Apollomics beats NewAmsterdam Pharma on 1 of the 1 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Aravive?

Aravive (NASDAQ:ARAV) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aravive's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company Overall Sentiment
Aravive Neutral
NewAmsterdam Pharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Summary

Aravive beats NewAmsterdam Pharma on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to bioAffinity Technologies?

NewAmsterdam Pharma (NASDAQ:NAMSW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, bioAffinity Technologies had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.78 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company Overall Sentiment
NewAmsterdam Pharma Neutral
bioAffinity Technologies Negative

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

NewAmsterdam Pharma beats bioAffinity Technologies on 2 of the 3 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BioVie?

BioVie (NASDAQ:BIVIW) and NewAmsterdam Pharma (NASDAQ:NAMSW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NewAmsterdam Pharma N/A N/A N/A

In the previous week, BioVie's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company Overall Sentiment
BioVie Neutral
NewAmsterdam Pharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NewAmsterdam Pharma$7.12MN/AN/AN/AN/A

Summary

NewAmsterdam Pharma beats BioVie on 1 of the 1 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMSW vs. The Competition

Export
MetricNewAmsterdam PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.88B$7.19B$13.38B
Dividend YieldN/A3.65%2.53%17.39%
P/E RatioN/A13.29273.9426.49
Price / SalesN/A1,239.12640.04108.72
Price / CashN/A126.5679.4153.24
Price / BookN/A16.1510.836.33
Net IncomeN/A-$22.65M$3.50B$381.96M
7 Day Performance-15.38%-4.16%-2.11%-0.41%
1 Month Performance-22.34%-12.16%-7.10%-4.85%
1 Year Performance-46.47%13.72%5.78%1.42%

NewAmsterdam Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMSW
NewAmsterdam Pharma
N/A$11.00
-8.3%		N/A-47.0%$0.00$7.12MN/A100
ALVOW
Alvotech
N/A$0.38
flat		N/A-65.7%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-6.0%		N/A-45.0%$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.22
-15.0%		N/A+70.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NAMSW) was last updated on 10/7/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel